You are here

  • Home
  • Archive
  • Volume 8, Issue 1
  • Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

Article metrics

Article menu

This article has a correction. Please see:

Download PDFPDF

Rheumatoid arthritis
Original research
Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study

 

Online download statistics by month:

Online download statistics by month: February 2022 to March 2024

AbstractFullPdf
Feb 202214061416591
Mar 2022606591263
Apr 2022576597268
May 2022416424226
Jun 2022325315155
Jul 2022368360205
Aug 2022338333214
Sep 2022363369258
Oct 2022456456188
Nov 2022449442247
Dec 2022321313163
Jan 2023404385218
Feb 2023383349228
Mar 2023494449245
Apr 2023351325165
May 2023415388217
Jun 2023412392216
Jul 2023321298169
Aug 2023326306149
Sep 2023355310154
Oct 2023451424187
Nov 2023447408170
Dec 2023293272171
Jan 2024333194144
Feb 2024270254174
Mar 2024315293231
Total11194106635616